Phase Ib study of pevonedistat, a NEDD8-activating enzyme inhibitor, in combination with docetaxel, carboplatin and paclitaxel, or gemcitabine, in patients with advanced solid tumors

Purpose This phase Ib study (NCT01862328) evaluated the maximum tolerated dose (MTD), safety, and efficacy of pevonedistat in combination with standard-of-care chemotherapies in patients with solid tumors. Methods Patients received pevonedistat with docetaxel (arm 1, n = 22), carboplatin plus paclit...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Invest New Drugs
Autori principali: Lockhart, A Craig, Bauer, Todd M., Aggarwal, Charu, Lee, Carrie B., Harvey, R Donald, Cohen, Roger B., Sedarati, Farhad, Nip, Tsz Keung, Faessel, Hélène, Dash, Ajeeta B., Dezube, Bruce J., Faller, Douglas V., Dowlati, Afshin
Natura: Artigo
Lingua:Inglês
Pubblicazione: Springer US 2018
Soggetti:
Phase I Studies
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC6510847/
https://ncbi.nlm.nih.gov/pubmed/29781056
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s10637-018-0610-0
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi